Vasodilator therapy and survival in chronic congestive heart failure  by Kukin, Marrick L.
1360
EDITORIALS	
Vasodilator Therapy and Survival in Chronic Congestive
Heart Failure*
MARRICK L. KUKIN, MD, FACC
New York. New York
The treatment of congestive heart failure has evolved con-
siderably over the past 15 years . State of the art therapy
utilizes a combination of three classes of medications : digi-
talis glycosides, diuretic drugs and vasodilators . There is
not, as yet, a consensus of opinion on other often utilized
medications for heart failure, including anticoagulant drugs,
antiarrhythmic agents and beta-adrenergic blocking agents .
In contrast, recent data have shown that some medica-
tions-oral phosphodiesterase inhibitors (1), some type I
antiarrhythmic agents (2) and calcium channel blockers
(3)-may actually be detrimental in heart failure .
In terms of the current conventional therapy in chronic
heart failure, the clinician has several choices within the
vasodilator category. Vasodilation can be achieved by
direct-acting drugs that cause arteriolar dilation-hydrala-
zine, for example-or by drugs that work through neurohor-
mona) antagonism with subsequent vasodilation-convert-
ing enzyme inhibitors, for example . If the immediate results
of vasodilation-decreased filling pressures and increased
cardiac output-were the sole goals, one would select the
most potent vasodilators to achieve these actions . However,
the physician who wants to use vasodilation as a means of
decreasing symptoms and increasing survival would choose
the drugs not on the basis of immediate hemodynamic
results, but on the basis of outcome of randomized, double-
blind survival trials in the target population .
Survival trials, Five prospective randomized clinical
trials ever the past 6 years provide the phy ian a
concerning morbidity and mortality that can guide a rational
approach to choosing appropriate vasodilator therapy . The
V-HEFT I trial (4) in 1986 showed that, compared with
placebo
. the combination of hydralazine and isosorbide
dinitrate had a favorable effect an mortality (with a border-
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line p value of 0.09) in patients in New York Heart Associ-
ation functional classes 11 and Ill . The CONSENSUS trial
(5) in 1987 showed a dramatic improvement in 6-month and
I-year survival in patients in functional class IV taking
enalapril compared with results in patients taking placebo .
After these trials, the next questions focused on the survival
benefits of converting enzyme inhibitor therapy in mild and
moderate heart failure and on a direct comparison of differ-
ent vasodilators in matched populations (positive controlled
trials) . Three new survival trials have answered many ques-
tions that remained after the first two survival trials .
The SOLVD treatment trial (6), which is the third double-
blind placebo-controlled heart failure survival trial with a
vasodilator, found a significant reduction in mortality in
patients in functional classes II and Ill taking enalapril
compared with that in patients taking placebo. The V-HEFT
11 trial (7), using two active therapy arms to test whether
direct-acting vasodilators (hydralazine) or vasodilators with
neurohormonal antagonism (enalapril) would differentially
affect mortality, found an improvement in survival is pa-
tients in functional classes 11 and Ill randomized to enalapril
therapy compared with the group randomized to the combi-
nation of hydralazine and isosorbide dinitrate . At the same
time, the combination of hydralazine and isosorbide dinitrate
improved exercise capacity (oxygen consumption) com-
pared with that in the patients treated with enalapril .
Hydralazine-captopril comparison, The Hy-C trial (8),
recently reported in this Journal, although not blinded, is the
latest survival trial to complement the previously published
data . This trial randomized patients with class III and IV
heart failure either to the combination of captopril and
isosorbide dinitrate or to the combination of hydralazine and
isosorbide dinitrate . Unlike the prevites trials, this study
was designed and completed at a single center .
This trial carefully tried to randomize patients to therapy
that was both tolerable and immediately effective in order to
test the effect on survival of actually taking the different
drugs . A total of 117 patients with class Ill and IV heart
failure referred to the transplant evaluation unit at the
University of California at Los Angeles with an elevated
mean pulmonary artery pressure or a depressed cardiac
output were randomly assigned to one of the two drug
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groups (combination theranv with captopril and isosorbide
dinitrate or with hydralazine and isosorbide dinitrate)- The
patients received "tailored therapy" (9) in which the hemo-
dynamic values achieved with nitroprusside and intravenous
furosemide were then matched by the oral drug regimen
assigned . If the assigned drug did not produce
-`acceptable"
hemodynamic status or caused significant side effects, the
alternate drug regimen was tried . Of 55 patients initially
randomized to treatment with captopril plus isosnrbide dini-
trate, 22 (4(%)
crossed over to the hydralazine plus isosor-
bide dinitrate group
. Only if (22%) of 49 patients assigned to
the combination of hydralazine and isosorbide dinitrate
crossed over to the captopril-isosorbide dinitrate regimen
(p = NS). The survival data are taken from 104 patients
discharged on drug therapy-the 44 patients treated with
captopril plus isosorbide (33 plus I I who crossed over to this
regimen) and the 60 patients treated with hydralazinu plus
isosorbide (38 plus 22 who crossed over to this regimen) .
Patients were followed up closely as outpatients . At I
year, the survival in the captopril-isosnrbide group was 81%
compared with 51% in the hydralazine-isosorbide group (p =
0 .05). By a Cox regression analysis, three variables indepen-
dently predicted survival: a low pulmonary capillary wedge
pressure with vasodilator therapy, serum sodium and capto-
pr0 therapy .
Study limitations. The results of this trial are consistent
with our expectations after the previous survival trials .
However, the methodology could have skewed the results
because of the crossover design of this trial (8) based on the
immediate hemodynamic goals of tailored therapy . Tailoring
long-term therapy on the basis of short-term hemodynamic
results can limit the use of drugs that have delayed hemo-
dynamic effects, and favor the use of drugs that provide
dramatic immediate herodynamic effects
. This bias may be
particularly significant with the converting enzyme inhibi-
which may take several weeks to show maximal
hemodynamic benefits (10-13)
.
In this study, 20 of the 22 patients who crossed over from
the captopril-isosorbide to the hydralazine-isosorbide regi-
men could conceivably have received long-term treatment
with captopril if tailored therapy had not been the initial
goal
. Eight of the 20 patients changed regimens because of
hypotension with short-term captopril therapy and 12
changed because the systemic vascular resistance could not
be lowered to "acceptable" levels
. The former group may
have received too high an initial dose of captopril, which is
a particular problem in patients with marked activation of
the renin-angiotensin system because their blood pressure is
dependent on retain (14). These patients often require and
tolerate a gradual increase in the dose of captopril over
several days. If the latter group had continued treatment
with the captopril-isosorbide combination for several weeks,
they might have shown a delayed (long-term) hemodynamic
response to captopril not found in the short term . Of
particular significance, this group of patients comprised the
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sickest patients
. as demonstrated by hvnonatremia (15) If
the serum sodium was < 135 mEg3iter in this trial . hemody-
namic goals were achieved in only 6 (33%) of the 18 patients
receiving the captopril-isosnrbide combination compared
with 12 171%) of the 17 patients receiving the hydralazine-
isosorbide combination (p = 0
.04) . Furthermore, among
patients whose pulmonary capillary wedge pressure after
vasodilator therapy was >16 mm Hg, I-year survival was
82% in those given captapril compared with only 18% in
those given hydralazine (p = 0 .01)
. One can only speculate
about long-term or delayed improvement in this hemody-
namic variable (and subsequently in survival) in the caplopril-
treated group.
Tailored therapy and the use of short-term
hemodynamic
studies, guide the choice ofa drug for long-term treatment
is
bused on two assumptions. The first is that tolerance does
not develop to the acute hemodynamic effects of the drug .
But this assumption is not always
true ; for example, pra-
zosin produces excellent immediate hemodynamic benefits
in patients with heart failure, but these effects are not
sustained during long-term treatment (16) . Tolerance has
been shown to develop during long-term hydralazine therapy
(17). whereas captopril therapy has been shown to produce
sustained hemodynamic benefit (12).
A second assumption is
that the hemodynamic effects of
drugs are correlated with their clinical effects .
This assump-
tion is also not necessarily valid ; certain arterial vasodila-
tors-minoxidil, for example-produce increases in cardiac
output but are associated with clinical deterioration rather
than clinical improvement (18).
Unfortunately, in the Hy-C study (8), a large number of
patients crossed over to the alternate therapy during the
initial "tailored" treatment. Such crossover may have
biased the data by preselecting "survivors" to be maintained
on captopril therapy and placing the most hyponatremic
patients (those who could not tolerate large doses of capto-
pril or meet hemodynamic targets) on hydealazine therapy .
There are no long-term hemodynamic data to demonstrate
continued hemodynamic efficacy (or tolerance) with either of
the drug groups . It is possible that the long-term hemody-
namic effects of hydralazine or captopril are not comparable
with their early effects .
Finally, the data on sadden death must be interpreted
with caution. Halter ambulatory electrocardiographic data
were obtained in 64 patients and amiodarone therapy was
initiated for high grade asymptomatic ventricular arrhyth-
mias . Approximately 66% of patients in this study were
taking an adtiarrhythmic drug (either a type I agent or
amiodarone). However, there were more patients in the
captopril-isosorbide group (48%) who were taking the hemo-
dynamically safer and perhaps less proan$ythmic amio-
darone than there were in the hydralazine-isosorbide group
(38%) .
Implications. This is the first survival trial (8) to show the
categoric value of converting enzyme inhibitors ; in the Hy-C
trial, caplopril was given, whereas the previous trials used
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enalapril . When viewed with the other vasodilator-heart
failure studies (with both placebo and positive controls), we
now have compelling evidence not only that vasodilators as
a class increase survival in heart failure, but that using
converting enzyme inhibitors inpatients in functional classes
II, 111 and IV improves survival compared with that
achieved with either placebo or direct-acting vasodilators
.
The probable mechanism for this enhanced survival is the
neurohormonal antagonism that is pharmacologically
achieved with captopril and enalapril . Given this preponder-
ance of clinical, hemodynamic and survival data, the vaso-
dilator of choice in patients with mild, moderate or severe
congestive heart failure should be a converting enzyme
inhibitor .
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